380 related articles for article (PubMed ID: 2170823)
21. Comparative studies of the ethynyl estrogens used in oral contraceptives. VII. Effects with and without progestational agents on ultracentrifugally fractionated plasma lipoproteins in humans, baboons, and beagles.
Goldzieher JW; Chenault CB; de la Peña A; Dozier TS; Kraemer DC
Fertil Steril; 1978 Nov; 30(5):522-33. PubMed ID: 214353
[TBL] [Abstract][Full Text] [Related]
22. Role of estrogens and progesterone in the etiology and prevention of endometrial cancer: review.
Gambrell RD; Bagnell CA; Greenblatt RB
Am J Obstet Gynecol; 1983 Jul; 146(6):696-707. PubMed ID: 6307050
[TBL] [Abstract][Full Text] [Related]
23. [Influence of progestins on adverse effects of oral contraceptives].
Wynn V
Contracept Fertil Sex (Paris); 1985 Jan; 13(1 Suppl):425-30. PubMed ID: 12280210
[TBL] [Abstract][Full Text] [Related]
24. A comparative study of the effects of an estradiol-releasing vaginal ring combined with an oral gestagen versus transdermal estrogen combined with a levonorgestrel-releasing IUD: clinical findings and endometrial response.
Kalogirou D; Antoniou G; Karakitsos P; Kalogirou O; Antoniou D; Giannikos L
Int J Fertil Menopausal Stud; 1996; 41(6):522-7. PubMed ID: 9010746
[TBL] [Abstract][Full Text] [Related]
25. Pharmacokinetics of oestrogens and progestogens.
Kuhl H
Maturitas; 1990 Sep; 12(3):171-97. PubMed ID: 2170822
[TBL] [Abstract][Full Text] [Related]
26. Comparative studies of the ethynyl estrogens used in oral contraceptives. VI. Effects with and without progestational agents on carbohydrate metabolism in humans, baboons, and beagles.
Goldzieher JW; Chenault CB; De La Pena A; Dozier TS; Kraemer DC
Fertil Steril; 1978 Aug; 30(2):146-53. PubMed ID: 98357
[TBL] [Abstract][Full Text] [Related]
27. Relationships between blood pressure, oral contraceptive use and metabolic risk markers for cardiovascular disease.
Godsland IF; Crook D; Devenport M; Wynn V
Contraception; 1995 Sep; 52(3):143-9. PubMed ID: 7587185
[TBL] [Abstract][Full Text] [Related]
28. Comparative metabolic effects of three types of combined oral contraceptive pills in Chinese women.
Prasad RN; Liew D; Ratnam SS
Contraception; 1989 Jan; 39(1):21-35. PubMed ID: 2521321
[TBL] [Abstract][Full Text] [Related]
29. Progestins and oral contraceptive-induced lipoprotein changes: a prospective study.
Lipson A; Stoy DB; LaRosa JC; Muesing RA; Cleary PA; Miller VT; Gilbert PR; Stadel B
Contraception; 1986 Aug; 34(2):121-34. PubMed ID: 3096633
[TBL] [Abstract][Full Text] [Related]
30. The adverse effects of hormonal therapy.
Bush TL
Cardiol Clin; 1986 Feb; 4(1):145-52. PubMed ID: 3518931
[TBL] [Abstract][Full Text] [Related]
31. Desogestrel, norgestimate, and gestodene: the newer progestins.
Kaplan B
Ann Pharmacother; 1995; 29(7-8):736-42. PubMed ID: 8520092
[TBL] [Abstract][Full Text] [Related]
32. [Hormonal contraception].
Van Cauwenberge JR
Rev Med Liege; 1992 May; 47(5):221-36. PubMed ID: 1604074
[TBL] [Abstract][Full Text] [Related]
33. Characteristics of the new progestogens in combination oral contraceptives.
Rebar RW; Zeserson K
Contraception; 1991 Jul; 44(1):1-10. PubMed ID: 1832625
[TBL] [Abstract][Full Text] [Related]
34. A comparative metabolic study of two low-estrogen-dose oral contraceptives containing desogestrel or gestodene progestins.
Crook D; Godsland IF; Worthington M; Felton CV; Proudler AJ; Stevenson JC
Am J Obstet Gynecol; 1993 Nov; 169(5):1183-9. PubMed ID: 8238183
[TBL] [Abstract][Full Text] [Related]
35. Reduced vaginal bleeding in postmenopausal women who receive combined norethindrone acetate and low-dose ethinyl estradiol therapy versus combined conjugated equine estrogens and medroxyprogesterone acetate therapy.
Simon JA; Liu JH; Speroff L; Shumel BS; Symons JP
Am J Obstet Gynecol; 2003 Jan; 188(1):92-9. PubMed ID: 12548201
[TBL] [Abstract][Full Text] [Related]
36. New progestogens in oral contraceptives.
Runnebaum B; Rabe T
Am J Obstet Gynecol; 1987 Oct; 157(4 Pt 2):1059-63. PubMed ID: 2960242
[TBL] [Abstract][Full Text] [Related]
37. Effects of newer oral contraceptives on the inhibition of coagulation and fibrinolysis in relation to dosage and type of steroid.
Jespersen J; Petersen KR; Skouby SO
Am J Obstet Gynecol; 1990 Jul; 163(1 Pt 2):396-403. PubMed ID: 2196812
[TBL] [Abstract][Full Text] [Related]
38. A norgestimate-containing oral contraceptive: review of clinical studies.
Kafrissen ME
Am J Obstet Gynecol; 1992 Oct; 167(4 Pt 2):1196-202. PubMed ID: 1415446
[TBL] [Abstract][Full Text] [Related]
39. Effect of estrogen/progestin potency on lipid/lipoprotein cholesterol.
Wahl P; Walden C; Knopp R; Hoover J; Wallace R; Heiss G; Rifkind B
N Engl J Med; 1983 Apr; 308(15):862-7. PubMed ID: 6572785
[TBL] [Abstract][Full Text] [Related]
40. The influence of pharmaceutical compounds on male fertility.
Neumann F; Diallo FA; Hasan SH; Schenck B; Traore I
Andrologia; 1976; 8(3):203-35. PubMed ID: 793446
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
